$ITOS News
Last published 4mo ago
- 4mo agoITOSMuna Therapeutics Announces CEO Transition as Clinical Pipeline AdvancesPR NewswireMuna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition....
- 1y agoITOSiTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value RightGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra
- 1y agoITOSiTeos Therapeutics Announces Its Intention to Wind Down OperationsGlobeNewswire- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a
- 1y agoITOSiTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsGlobeNewswire– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development
- 1y agoITOSiTeos Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and
- 1y agoITOSiTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025GlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 1y agoITOSiTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswire- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed enrollment of
- 1y agoITOSiTeos Announces 2025 Strategic Priorities and Anticipated MilestonesGlobeNewswire- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase
- 1y agoITOSiTeos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 1y agoITOSiTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology CongressGlobeNewswire- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose
- 1y agoITOSiTeos to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 1y agoITOSiTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at
- 2y agoITOSiTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology CongressGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsGlobeNewswire- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug +
- 2y agoITOSiTeos to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024GlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and investment balance of
- 2y agoITOSiTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical OfficerGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSKGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every
- 2y agoITOSiTeos Therapeutics Announces $120 Million Registered Direct OfferingGlobeNewswire- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma cash position of
- 2y agoITOSiTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024GlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewswire- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial
- 2y agoITOSiTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024GlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 2y agoITOSiTeos Announces 2024 Strategic Priorities and Anticipated MilestonesGlobeNewswire- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio clinical data readouts anticipated in second
- 2y agoITOSiTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 2y agoITOSiTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 3y agoITOSiTeos Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswire- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in
- 3y agoITOSNCRSPGINATL+1NCR Atleos Set to Join S&P SmallCap 600PR NewswireNEW YORK, Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE:NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18.
- 3y agoITOSiTeos to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
- 3y agoITOSiTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswire– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new
- 3y agoGILDGSKITOSONCY+1New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of ActionPR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are
- 3y agoITOSiTeos Reports First Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswire– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine
- 3y agoITOSiTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewswire- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a
- 3y agoITOSiTeos to Present at Cowen 43rd Annual Health Care ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 3y agoITOSiTeos to Present at SVB Securities Global Biopharma ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 3y agoITOSiTeos Provides Business Updates and Clinical Development Plans for 2023GlobeNewswire- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor
- 3y agoITOSiTeos to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 3y agoITOSiTeos to Present at the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
- 4y agoITOSiTeos Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewswire– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK's anti-PD-1 Jemperli (dostarlimab) in first line, metastatic non-small cell lung cancer – Phase 2 trials with
- 4y agoITOSiTeos Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK's anti-PD-1 Jemperli (dostarlimab) - Enrolling patients with non-small cell lu
- 4y agoITOSiTeos to Present at the 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewswireWATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics f
- 4y agoITOSDomain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific OfficerBusiness WireDr Leroy will oversee the pipeline of the company in immuno-oncology and will be responsible for advancing the GPCR programs to the clinic Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative dru
- 4y agoITOSiTeos Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireEnrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS's novel CELMoD agent, iberdomide. Enrolling patients in the biomarker cohort in an ongoing clin
- 4y agoITOSiTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022GlobeNewswireTreatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody In preclinical studies and in blood samples from patients wit
- 4y agoITOSiTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswire- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combinatio
- 4y agoITOSiTeos to Present at the Cowen 42nd Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-